The CEO of an Australian IT startup has designed a personalized cancer vaccine for his dog diagnosed with a terminal illness using artificial intelligence (AI) and confirmed its therapeutic effects.

Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid ...

Immunis Inc. has struck a licensing deal with Japanese material manufacturer Toray Industries Inc. to develop a potential treatment for Parkinson’s-associated involuntary movement.

The Hunter syndrome space suffered a setback in February when the FDA turned down REGENXBIO's investigational gene therapy, ...